Colleen Tupper Sells 19,710 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Free Report) CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $32.43 on Friday. The company has a market capitalization of $1.06 billion, a P/E ratio of 13.51 and a beta of 1.06. The company has a 50-day simple moving average of $36.31 and a 200 day simple moving average of $33.39. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98.

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The company had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently bought and sold shares of the stock. Principal Securities Inc. bought a new stake in Collegium Pharmaceutical in the fourth quarter worth about $40,000. China Universal Asset Management Co. Ltd. raised its position in Collegium Pharmaceutical by 320.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after acquiring an additional 2,877 shares in the last quarter. Assetmark Inc. raised its position in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares in the last quarter. Sheaff Brock Investment Advisors LLC bought a new stake in Collegium Pharmaceutical in the first quarter worth about $204,000. Finally, Versor Investments LP bought a new stake in Collegium Pharmaceutical in the third quarter worth about $207,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on COLL shares. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a report on Friday, May 10th. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Needham & Company LLC downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $39.00.

View Our Latest Stock Report on Collegium Pharmaceutical

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Stories

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.